Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
ILA 56.9
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Nextgen Biomed Ltd develops topical treatment for psoriasis. The company was formerly known as Sela Group.Com Ltd. and changed its name to Nextgen Biomed Ltd in February 2010. Nextgen Biomed Ltd was incorporated in 1990 and is based in Tel Aviv, Israel.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Data is available to registered users only
